Isolated hepatic perfusion for ocular melanoma metastasis: Registry data suggests a survival benefit

Annals of Surgical Oncology

Volumn 21, Issue 2, 2014, Pages 466-472

  Olofsson, R ^a   Cahlin, C ^a   All Ericsson, C ^b   Hashimi, F ^a   Mattsson, J ^a   Rizell, M ^a   Lindner P ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA METASTASIS; MIDDLE AGED; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; SWEDEN; UVEA MELANOMA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EYE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; PERFUSION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REGISTRIES; SURVIVAL RATE; SWEDEN; YOUNG ADULT;

EID: 84896823418     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3304-z     Document Type: Article

References (16)

1. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639-43.
2. Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol. 2009;35:1192-7.
3. Leyvraz S, Suciu S, Piperno-Neumann S, Baurain J.-F, Zdzienicki M, Testori A, et al. Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: final results of the EORTC 18021 study. J Clin Oncol. 2012;30(15 suppl):8532.
4. Sharma KV, Gould JE, Harbour JW, Linette GP, Pilgram TK, Dayani PN, et al. Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol. 2008;190:99-104.
5. Ausman RK, Aust JB. Isolated perfusion of the liver with HN2. Surg Forum. 1960;10:77-9.
6. Rizell M, Mattson J, Cahlin C, Hafstrom L, Lindner P, Olausson M. Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res. 2008;18:120-6.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
8. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-13.
9. Duh EJ, Schachat AP, Albert DM, Patel SM. Long-term survival in a patient with uveal melanoma and liver metastasis. Arch Ophthalmol. 2004;122:285-7.
10. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062-70.
11. Alexander HR, Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:6343-9.
12. Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res. 2004;14:67-72.
13. van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol. 2008;15:1891-8.
14. Pingpank JF, Hughes MS, Alexander HR, Faries MB, Zager JS, Royal RE, et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol. 2010;28(18 suppl):LBA8512.
15. Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41-8.
16. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:782-9.